Parametrica Management’s Kyntra Bio KYNB Stock Holding History

Parametrica Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-206	Closed	-$209K	–	113
2020 Q2	$209K	Buy	+206	New	+$191K	0.23%	108

Other funds holding KYNB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Parametrica Management's KYNB Position: Q3 2020 in Review

Parametrica Management sold out of Kyntra Bio (KYNB) in Q3 2020, closing a stake of 206 shares — an estimated $209K sold.

Parametrica Management first reported a position in KYNB in Q2 2020 and held it in 1 quarter. The position peaked at $209K in Q2 2020. 208 funds tracked by Wall St. Rank hold KYNB as of Q3 2020.

Parametrica Management reported no remaining Kyntra Bio position as of Q3 2020 after selling out during the quarter.
Parametrica Management sold 206 Kyntra Bio shares in Q3 2020, an estimated $209K.
Parametrica Management first reported a position in Kyntra Bio in Q2 2020 and held it in 1 quarter.
Parametrica Management's Kyntra Bio position peaked at $209K in Q2 2020.
208 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2020.

Based on Parametrica Management's 13F filing for Q3 2020, filed 13 Nov 2020.